Concepts of immunostimulation to increase antiparasitic drug action

Parasitology Research

Volumn 90, Issue SUPPL. 2, 2003, Pages S97-S104

  Masihi, K Noel ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; CYTOKINE; GAMMA INTERFERON; IMIQUIMOD; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LEISHMANIA VACCINE; LYMPHOTOXIN; MESSENGER RNA; MURAMYL DIPEPTIDE; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PARASITE ANTIGEN; RESIQUIMOD; STAT4 PROTEIN; TRYPANOSOMA CRUZI VACCINE;

DRUG ACTIVITY; DRUG EFFECT; HELPER CELL; HUMAN; IMMUNOSTIMULATION; LEISHMANIASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; TOXOPLASMA GONDII; TOXOPLASMOSIS; TRYPANOSOMIASIS;

SCHISTOSOMA; SCHISTOSOMA MANSONI; TOXOPLASMA GONDII; TRYPANOSOMA; TRYPANOSOMA CRUZI;

EID: 0037963683     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-002-0774-5     Document Type: Review

References (59)

1. Ahuja SS, Reddick RL, Sato N, Montalbo E, Kostecki V, Zhao W, Dolan MJ, Melby PC, Ahuja SK (1999) Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol 163:3890-3897
2. Araujo Z, Heremans H, Stordeur P, Wissing M, Goldman M, Castes M, Carlier Y (2000) IFN-gamma, IL-4, IL-10 and IL-12 gene expression in BCG-Leishmania vaccination of Trypanosoma cruzi-infected mice. Vaccine 18:1822-1829
3. Bancroft AJ, McKenzie ANJ, Grencis RK (1998) A critical role for IL-13 in resistance to intestinal nematode infection. J Immunol 160:3453-3461
4. Bancroft AJ, Artis D, Donaldson DD, Sypek JP, Grencis RK (2000) Gastrointestinal nematode expulsion in IL-4 knockout mice is IL-13 dependent. Eur J Immunol 30:2083-2091
5. Barral-Neto MA, Barral CE, Browne II, Skeiky YAW, Ellingworth LR, Twardzik DR, Reed SG (1992) Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257:545-548
6. Barreto ML, Rodrigues LC, Silva RC, Assis AM, Reis MG, Santos CA, Blanton RE (2000) Lower hookworm incidence, prevalence, and intensity of infection in children with a Bacillus Calmette-Guerin vaccination scar. J Infect Dis 182:1800-1803
7. Bermudez LE, Covaro G, Remington J (1993) Infection of murine macrophages with Toxoplasma gondii is associated with release of transforming growth factor beta and downregulation of expression of tumor necrosis factor receptors. Infect Immun 61:4126-4130
8. Bliss SK, Butcher BA, Denkers EY (2000) Rapid recruitment of neutrophils containing prestored IL-12 during microbial infection. J Immunol 165:4515-4521
9. Bourreau E, Prevot G, Pradinaud R, Launois P (2001) Unresponsiveness of specific T cells to IL-12 is associated with active cutaneous leishmaniasis owing to Leishmania guyanensis. Scand J Immunol 54:335-339
10. Buates S, Matlashewski G (1999) Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 179:1485-1494
11. Bungiro RD Jr, Goldberg M, Suri PK, Knopf PM (1999) Interleukin-12 as an adjuvant for an antischistosome vaccine consisting of adult worm antigens: protection of rats from cercarial challenge. Infect Immun 67:2340-2348
12. Chao CC, Hu S, Gekker G, Novick WJ, Remington JS, Peterson PK(1993) Effects of cytokines on multiplication of Toxoplasma gondii in microglial cells. J Immunol 150:3403-3410
13. Chen G, Darrah PA, Mosser DM (2001) Vaccination against the intracellular pathogens Leishmania major and L. amazonensis by directing CD40 ligand to macrophages. Infect Immun 69:3255-3263
14. Chiaramonte MG, Hesse M, Cheever AW, Wynn TA (2000) CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism. J Immunol 164:973-985
15. Corral RS, Petray PB (2000) CpG DNA as aTh1-promoting adjuvant immunization against Trypanosoma cruzi. Vaccine 19:234-242
16. Doherty TM, Coffman RL (1999) Ability of macrophage subsets to transfer resistance to routine leishmaniasis is dependent on IL-12 production. Eur Immunol 29:522-529
17. Dvoroznakova E, Boroskova Z, Dubinsky P, Tomasovicova O, Hribalova V, Machnicka B (1999) Immunomodulative effect of muramyldipeptide in mice with larval toxocarosis. Parasitol Res 85:1034-1040
18. Eslami Z, Gaucher D, Tanner CE (1996) Synergism of IL-2-stimulated splenocytes and Pentostam enhances the killing of Leishmania donovani in vitro. Clin Immunol Immunopathol 81:74-81
19. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN (2000) Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol 164:2585-2591
20. Fernandes AP, Carvalho FA, Tavares CA, Santiago HC, Castro GA, Tafuri WL, Ferreira LA, Gazzinelli RT (2001) Combined interleukin-12 and topical chemotherapy for established Leishmanias drastically reduces tissue parasitism and relapses in susceptible mice. J Infect Dis 183:1646-1652
21. Finkelman FD, Wynn TA, Donaldson DD, Urban JF (1999) The role of IL-13 in helminth-induced inflammation and protective immunity against nematode infections. Curr Opin Immunol 11:420-426
22. Follador I, Araujo C, Orge G, Cheng LH, Carvalho LP de, Bacellar O, Almeida RP, Carvalho EM (2002) Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor. Vaccine 20:1365-1368
23. Gabaglia CR, Pedersen B, Hitt M, Burdin N, Sercarz EE, Graham FL, Gauldie J, Braciak TA (1999) A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4 expressing vector increases disease susceptibility in B10.D2 mice. J Immunol 162:753-760
24. Heinze FP, Schoenhaut DM, Rerko RM, Rosser LE, Gately MK(1993) Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 177:1505-1509
25. Jones DE, Buxbaum LU, Scott P (2000) IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J Immunol 165:364-372
26. Kenney RT, Sacks DL, Sypek JP, Vilela L, Garn AA, Evans-Davis K (1999) Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 163:4481-4488
27. Khan IA, Casciotti L (1999) IL-15 prolongs the duration of CD8+ T cell-mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii. J Immunol 163:4503-4509
28. Kole L, Das L, Das PK(1999) Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis. J Infect Dis 180:811-820
29. Kremer IB, Gould MP, Cooper KD, Heinzel FP (2001) Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice. Infect Immun 69:673-680
30. Lehmann J, Enssle KH, Lehmann I, Emmendorfer A, Lohmann-Matthes ML (2000) The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res 20:63-77
31. Li J, Hunter CA, Farrell JP (1999) Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol 162:974-979
32. Luty AJ, Perkins DJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, Greve B, Matousek P, Herbich K, Schmid D, Weinberg JB, Kremsner PG (2000) Low interleukin-12 activity in severe Plasmodium falciparum malaria. Infect Immun 68:3909-3915
33. Masihi KN (1994) Immunotherapy of infections. Dekker, New York
34. Masihi KN (2000) Immunomodulators in infectious diseases: panoply of possibilities. Int J Immunopharmacol 22:1083-1091
35. Masihi KN (2001) Fighting infection using immunomodulatory agents. Expert Opin Biol Ther 1:641-653
36. Matsumoto S, Yukitake H, Kanbara H, Yarnada H, Kitamura A, Yamada T (2000) Mycobacterium bovis bacillus Calmette-Guerin induces protective immunity against infection by Plasmosdium yoelii at blood-stage depending on shifting immunity toward Th1 type and inducing protective IgG2a after the parasite infection. Vaccine 19:779-787
37. Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, McKenzie AN (2000) IL13 is a susceptibility factor for Leishmania major infection. J Immunol 164:1458-1462
38. McDowell MA, Sacks DL (1999) Inhibition of host cell signal transduction by Leishmania: observations relevant to the selective impairment of IL-12 responses. Curr Opin Microbiol 2:438-443
39. McKenzie GJ, Bancroft A, Grencis RK, McKenzie AN (1998) A distinct role for interleukin-13 in Th2 cell-mediated immune responses. Curr Biol 8:339-342
40. Mohan K, Sam H, Stevenson MM (1999) Therapy with a combination of low doses of interleukin 12 and chloroquine completely cures blood-stage malaria, prevents severe anemia, and induces immunity to reinfection. Infect Immun 67:513-519
41. Murray HW, Montelibano C, Peterson R, Sypek JP (2000) Interleukin-12 regulates the response to chemotherapy, in experimental visceral leishmaniasis. J Infect Dis 182:1497-1502
42. Nickdel MB, Roberts F, Brombacher F, Alexander J, Roberts CW (2001) Counter-protective role for interleukin-5 during acute Toxoplasma gondii infection. Infect Immun 69:1044-1052
43. Perez-Santos JL, Talamas-Rohana P (2001) In vitro indomethacin administration upregulates interleukin-12 production and polarizes the immune response towards a Th1 type in susceptible BALB/c mice infected with Leishmania mexicana. Parasite Immunol 23:599-606
44. Quinones M, Ahuja SK, Melby PC, Pate L, Reddick RL, Ahuja SS (2000) Preformed membrane-associated stores of interleukin (IL)-12 are a previously unrecognized source of bioactive IL-12 that is mobilized within minutes of contact with an intracellular parasite. J Exp Med 192:507-516
45. Reichmann G, Walker W, Villegas EN, Craig L, Cai G, Alexander J, Hunter CA (2000) The CD40/CD40 ligand interaction is required for resistance to toxoplasmic encephalitis. Infect Immun 68:1312-1318
46. Rivier D, Bovay P, Shah R, Didisheim S, Mauel J (1999) Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection. Parasite Immunol 21:461-473
47. Saha B, Saini A, Germond R, Perrin PJ, Harlan DM, Davis TA (1999) Susceptibility or resistance to Leishmania infection is dictated by the macrophages evolved under the influence of IL-3 or GM-CSF. Eur J Immunol 29:2319-2329
48. Sakai T, Hisaeda H, Nakano Y, Ishikawa H, Maekawa Y, Ishii K, Nitta Y, Miyazaki J, Himeno K (2000) Gene gun-mediated delivery of an interleukin-12 expression plasmid protects against infections with the intracellular protozoan parasites Leishmania major and Trypanosoma cruzi in mice. Immunology 99:615-624
49. Satoskar AR, Rodig S, Telford SR, Satoskar AA, Ghosh SK, Lichtenberg F von, David JR (2000) IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur J Immunol 30:834-839
50. Sauder DN (2000) Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 43:S6-S11
51. Silva JS, Twrdzik DR, Reed SG (1991) Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta). J Exp Med 174:539-545
52. Stacey KJ, Blackwell JM (1999) Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 67:3719-3726
53. Stamm LM, Satoskar AA, Ghosh SK, David JR, Satoskar AR (1999) STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis. Eur J Immunol 29:2524-2529
54. Stevenson MM, Su Z, Sam H, Mohan K (2001) Modulation of host responses to blood-stage malaria by interleukin-12: from therapy to adjuvant activity. Microbes Infect 2001:49-59
55. Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC, Vogel JC (1999) Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci USA 96:6970-6975
56. Yamakami K, Akao S, Sato M, Nitta Y, Miyazaki J, Tadakuma T (2001) A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection. Parasitol Int 50:81-91
57. Yap G, Pesin M, Sher A (2000) Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii. J Immunol 165:628-631
58. Zhang Y, Denkers EY (1999) Protective role for interleukin-5 during chronic Toxoplasma gondii infection. Infect Immun 67:4383-4392
59. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, Heeg K (1998) CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal routine leishmaniasis. J Immunol 160:3627-3630